ETrade Capital Management’s Novartis NVS Stock Holding History

ETrade Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$6.8M	Sell	78,229 -18,893	-19%	-$1.64M	0.13%	84
2020 Q2	$8.48M	Buy	97,122 +13,669	+16%	+$1.18M	0.18%	66
2020 Q1	$6.88M	Buy	83,453 +9,430	+13%	+$841K	0.18%	70
2019 Q4	$7.01M	Buy	74,023 +4,461	+6%	+$400K	0.16%	74
2019 Q3	$6.04M	Buy	69,562 +973	+1%	+$87.4K	0.15%	82
2019 Q2	$6.26M	Sell	68,589 -7,980	-10%	-$675K	0.17%	62
2019 Q1	$6.6M	Buy	76,569 +218	+0.3%	+$17.5K	0.19%	52
2018 Q4	$5.87M	Buy	76,351 +14,257	+23%	+$1.11M	0.19%	52
2018 Q3	$4.79M	Buy	62,094 +1,298	+2%	+$96K	0.14%	84
2018 Q2	$4.12M	Buy	60,796 +8,284	+16%	+$572K	0.13%	86
2018 Q1	$3.8M	Buy	52,512 +10,717	+26%	+$816K	0.12%	90
2017 Q4	$3.14M	Buy	41,795 +7,699	+23%	+$581K	0.1%	110
2017 Q3	$2.62M	Buy	34,096 +827	+2%	+$62.5K	0.09%	126
2017 Q2	$2.49M	Sell	33,269 -30,212	-48%	-$2.14M	0.1%	118
2017 Q1	$4.22M	Buy	63,481 +1,867	+3%	+$124K	0.17%	59
2016 Q4	$4.02M	Buy	61,614 +26,989	+78%	+$1.75M	0.18%	59
2016 Q3	$2.45M	Buy	34,625 +6,221	+22%	+$453K	0.12%	100
2016 Q2	$2.1M	Buy	28,404 +1,616	+6%	+$112K	0.11%	116
2016 Q1	$1.74M	Buy	26,788 +820	+3%	+$55.8K	0.1%	133
2015 Q4	$2M	Buy	25,968 +3,334	+15%	+$265K	0.12%	106
2015 Q3	$1.86M	Sell	22,634 -358	-2%	-$31.9K	0.11%	110
2015 Q2	$2.03M	Buy	22,992 +755	+3%	+$69.3K	0.12%	107
2015 Q1	$1.97M	Sell	22,237 -1,500	-6%	-$133K	0.12%	115
2014 Q4	$1.97M	Sell	23,737 -97	-0.4%	-$8.04K	0.12%	115
2014 Q3	$2.01M	Buy	23,834 +692	+3%	+$56K	0.13%	97
2014 Q2	$1.88M	Buy	23,142 +1,427	+7%	+$112K	0.12%	121
2014 Q1	$1.66M	Buy	21,715 +2,274	+12%	+$166K	0.12%	115
2013 Q4	$1.4M	Buy	19,441 +578	+3%	+$40.2K	0.11%	128
2013 Q3	$1.3M	Buy	18,863 +3,934	+26%	+$260K	0.12%	96
2013 Q2	$946K	Buy	+14,929	New	+$971K	0.1%	100

Other funds holding NVS

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Mawer Investment Management Calgary, Alberta, Canada $15.4B AUM 10.9% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Aristotle Capital Management Los Angeles, California $47.8B AUM 13.38% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ETrade Capital Management's NVS Position: Q3 2020 in Review

ETrade Capital Management reduced its Novartis (NVS) stake by 19% in Q3 2020, selling an estimated $1.64M and leaving 78,229 shares worth $6.8M. The position accounts for 0.13% of the portfolio, ranked #84.

ETrade Capital Management first reported a position in NVS in Q2 2013 and has held it in 30 quarters since. The position peaked at $8.48M in Q2 2020. 1,119 funds tracked by Wall St. Rank hold NVS as of Q3 2020.

ETrade Capital Management held 78,229 shares of Novartis worth $6.8M as of Q3 2020.
ETrade Capital Management sold 18,893 Novartis shares in Q3 2020, an estimated $1.64M.
Novartis made up 0.13% of ETrade Capital Management's portfolio in Q3 2020, its #84 holding.
ETrade Capital Management first reported a position in Novartis in Q2 2013 and has held it in 30 quarters since.
ETrade Capital Management's Novartis position peaked at $8.48M in Q2 2020.
1,119 funds tracked by Wall St. Rank held Novartis as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.